Shares of Iterum Therapeutics (ITRM) touched a new 52-week high of $2.42 during intraday trading yesterday, reflecting a gain of more than 98% over the past 1 month.
Iterum is focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug-resistant pathogens in both community and hospital settings.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com